Literature DB >> 9032338

In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues.

J K Wong1, C C Ignacio, F Torriani, D Havlir, N J Fitch, D D Richman.   

Abstract

High rates of mutation and replication of human immunodeficiency virus (HIV) allow for the continuous generation of diverse genetic variants in vivo. Selective pressures within the microenvironments of different anatomic compartments result in the emergence of dominant quasispecies which can be distinguished by their envelope sequences. It is not known whether comparable tissue-specific selective pressures lead to the independent evolution of pol sequences within different tissue compartments, nor is it known how differing rates of virus turnover in tissues might affect the pace of such evolution. These issues are of importance for the formulation of a model for the emergence of drug resistance in vivo and for a general understanding of virus trafficking and virus turnover. Regions of the HIV type 1 reverse transcriptase (RT) which carry the majority of the known resistance codons to RT inhibitors (700 nucleotides from each clone) were cloned and sequenced directly from autopsied brain, spleen, and lymph node specimens from four subjects who had received zidovudine therapy. Clones from proviral DNA (143) and from viral cDNA (14) were analyzed. In three of four subjects, a discordance in distribution of resistance codons was noted. Moreover, brain-derived sequences appeared to be phylogenetically distinct from spleen- and lymph node-derived sequences even after exclusion of resistance codons from analysis. In each case, evidence for differential immune selective pressure, based on comparison of inferred amino acid sequences corresponding to known major histocompatibility complex class I cytotoxic T-lymphocyte epitopes, was found. These observations support the concept of anatomically distinct, independently evolving quasispecies (virodemes).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032338      PMCID: PMC191294     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Evolution of human immunodeficiency virus type 1 nef and long terminal repeat sequences over 4 years in vivo and in vitro.

Authors:  S Delassus; R Cheynier; S Wain-Hobson
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

2.  Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy.

Authors:  S Koenig; H E Gendelman; J M Orenstein; M C Dal Canto; G H Pezeshkpour; M Yungbluth; F Janotta; A Aksamit; M A Martin; A S Fauci
Journal:  Science       Date:  1986-09-05       Impact factor: 47.728

3.  Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations.

Authors:  V K Pathak; H M Temin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

4.  Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex.

Authors:  F A Schmitt; J W Bigley; R McKinnis; P E Logue; R W Evans; J L Drucker
Journal:  N Engl J Med       Date:  1988-12-15       Impact factor: 91.245

5.  An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes.

Authors:  A Hosmalin; M Clerici; R Houghten; C D Pendleton; C Flexner; D R Lucey; B Moss; R N Germain; G M Shearer; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

6.  Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection.

Authors:  P A Pizzo; J Eddy; J Falloon; F M Balis; R F Murphy; H Moss; P Wolters; P Brouwers; P Jarosinski; M Rubin
Journal:  N Engl J Med       Date:  1988-10-06       Impact factor: 91.245

7.  Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro.

Authors:  K Kusumi; B Conway; S Cunningham; A Berson; C Evans; A K Iversen; D Colvin; M V Gallo; S Coutre; E G Shpaer
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

8.  Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Authors:  R Yarchoan; C F Perno; R V Thomas; R W Klecker; J P Allain; R J Wills; N McAtee; M A Fischl; R Dubinsky; M C McNeely
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

9.  Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex.

Authors:  R Yarchoan; J M Pluda; R V Thomas; H Mitsuya; P Brouwers; K M Wyvill; N Hartman; D G Johns; S Broder
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

10.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

Authors:  Y Koyanagi; S Miles; R T Mitsuyasu; J E Merrill; H V Vinters; I S Chen
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

View more
  117 in total

Review 1.  Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1.

Authors:  A D Kashuba; J R Dyer; L M Kramer; R H Raasch; J J Eron; M S Cohen
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Genetic drift and within-host metapopulation dynamics of HIV-1 infection.

Authors:  S D Frost; M J Dumaurier; S Wain-Hobson; A J Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

Review 3.  Human immunodeficiency virus-associated dementia: an evolving disease.

Authors:  Justin C McArthur; Norman Haughey; Suzanne Gartner; Kathy Conant; Carlos Pardo; Avi Nath; Ned Sacktor
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

4.  Role of microglial cells in selective replication of simian immunodeficiency virus genotypes in the brain.

Authors:  Tahar Babas; Daniel Muñoz; Joseph L Mankowski; Patrick M Tarwater; Janice E Clements; M Christine Zink
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with kaposi's sarcoma.

Authors:  Marta Boffito; Patrick G Hoggard; David J Back; Stefano Bonora; Agostino Maiello; Anna Lucchini; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy.

Authors:  Binshan Shi; Christina Kitchen; Barbara Weiser; Douglas Mayers; Brian Foley; Kimdar Kemal; Kathryn Anastos; Marc Suchard; Monica Parker; Cheryl Brunner; Harold Burger
Journal:  Virology       Date:  2010-05-08       Impact factor: 3.616

7.  Controlling the Evolution of Resistance.

Authors:  Rutao Luo; Lamont Cannon; Jason Hernandez; Michael J Piovoso; Ryan Zurakowski
Journal:  J Process Control       Date:  2011-03-01       Impact factor: 3.666

8.  Subpopulations of equine infectious anemia virus Rev coexist in vivo and differ in phenotype.

Authors:  Prasith Baccam; Robert J Thompson; Yuxing Li; Wendy O Sparks; Michael Belshan; Karin S Dorman; Yvonne Wannemuehler; J Lindsay Oaks; James L Cornette; Susan Carpenter
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Macrophage/microglial accumulation and proliferating cell nuclear antigen expression in the central nervous system in human immunodeficiency virus encephalopathy.

Authors:  Tracy Fischer-Smith; Sidney Croul; Aderonke Adeniyi; Katarzyna Rybicka; Susan Morgello; Kamel Khalili; Jay Rappaport
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

10.  The reverse transcriptase sequence of human immunodeficiency virus type 1 is under positive evolutionary selection within the central nervous system.

Authors:  Kelly J Huang; Gerald M Alter; Dawn P Wooley
Journal:  J Neurovirol       Date:  2002-08       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.